Stakkars kar fra Nordnet med sin stopp loss 
2 Likes
Var det det som skjedde?
Forstår ikke greia med SL…
jeg hadde tenkt å ligge ute og fiske her, men hadde dessverre ikke noen ordre inne. Ser uansett ut som det går å få litt på 9 tallet nå
3 Likes
NattoPharma will release its first half 2017 financial results on Wednesday 16th August 2017 at approximately 08:00 CET. The first half 2017 financial report will be made available at www.nattopharma.com and at www.oslobors.no. The same day, starting at 10:00 am, the company will host a webcast with a presentation of the results, followed by an online Q&A session. Please follow the below link to join the web-cast, http://webtv.hegnar.no/presentation.php?webcastId=63184487 The presentation will be held by CEO Daniel H. Rosenbaum and CFO Kjetil Ramsøy. For more information, please contact: Kjetil Ramsøy CFO, NattoPharma E-mail: kjetil.ramsoy@nattopharma.com This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
4 Likes
Hyggelig å se at noen laster opp på 10.15 i dag
1 Like
Clinical single-arm trial with renal transplant recipients shows improved arterial stiffness OSLO, NORWAY and METUCHEN, NJ (August 16th, 2017) - A new study1 of renal transplant recipients, a group shown to express subclinical vitamin K deficiency, examined whether K2 supplementation would correct this deficiency and thus improve arterial stiffness. The study has published in Journal of the American Society of Hypertension, and the vitamin K2 used in the study was MenaQ7® Vitamin K2 as MK-7 from NattoPharma. This Lebanese study evaluated in the KING trial (a single-arm pilot study) to see if there is an association between vitamin K2 supplementation and the change in both subclinical vitamin K status and indices of arterial stiffness among 60 renal transplant recipients with stable graft function. The results showed that 8 weeks of MK-7 supplementation (360 mcg/day as MenaQ7®) was associated with significant improvement in arterial stiffness and 24-hour peripheral and central pressures. The mean reduction in cfPWV was 1.4 m/s, which was well beyond the reduction of 1 m/s recommended for a clinically relevant vascular effect. “While our previous cardiovascular study in healthy postmenopausal women showed an improvement in arterial elasticity after 3 years of supplementation, the results collected in this trial are staggering, especially as the statistically significant effect was seen very quickly,” says Hogne Vik, chief medical officer of NattoPharma. "After just 8 weeks of MK-7 supplementation, low vitamin K status represented by dpucMGP level was significantly reduced by 55.1%. Moreover, supplementation was associated with a 14.2% reduction in mean cfPWV. “One can assume that longer MK-7 supplementation may lead to even better results, and secure improvement in cardiovascular outcomes in renal transplant patients.” According to the researchers, prior observational studies have shown the prevalence of subclinical vitamin K deficiency has been reported to be as high as 80% in the renal transplant population. Moreover, in kidney transplant recipients, Vitamin K insufficiency, expressed as a high circulating level of dp -ucMGP (dephosphorylated-uncarboxylated matrix Gla protein, or “inactive” MGP, a K-dependent protein), is associated independently with increased risk of mortality. However, any studies to date have not addressed whether vitamin K supplementation may lead to improved outcomes after kidney transplantation. In addition, MK-7 supplementation improved vitamin K status, which was represented by the reduction in dp-ucMGP concentrations. A positive correlation was present between the reduction in arterial stiffness, a surrogate of early cardiovascular disease, and the circulating concentration of dp-ucMGP, a marker of subclinical vascular vitamin K deficiency and calcification. The main conclusion was that, among renal transplant recipients with stable graft function, vitamin K2 supplementation was associated with improvement in subclinical K deficiency and arterial stiffness. According to the researchers, the findings from this trial support the hypothesis that subclinical vitamin K deficiency may be a modifiable cardiovascular risk factor and may improve with MK-7 supplementation. “NattoPharma was excited to participate in this clinical trial,” adds Dr. Vik. “We have dedicated ourselves to cultivating an understanding of the benefits Vitamin K2 offers to human health, and in that work have recognized that vitamin K2 deficiency can have serious implications on arterial health. This study adds to the body of evidence confirming the cardiovascular support MenaQ7® Vitamin K2 as MK-7 provides, and continues to solidify the hope this important nutrient offers the global population.” Reference: 1 Mansour AG et al. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients - a single-arm, single-center clinical trial. J Am Soc Hypertens. 2017 Jul 13. Pii: S1933-1711(17)30255-3. # # # About NattoPharma and MenaQ7® NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com. For more information, please contact: Kate Quackenbush, NattoPharma Director of Communications Phone: 609-643-0749 x 220 E-mail: kate.quackenbush@nattopharma.com
3 Likes
Noen som følger presentasjonen?
Hva synes du om tallene?
H1 2017
· Revenue rose by 18,6% to NOK 30,6 million
· Gross Margin for the period was 45,8 %,
· Positive adjusted EBITDA of NOK 1,5 million for the supplement business
Fra Q4 2016:
4th Quarter 2016
· Revenue rose by 44 % to NOK 15,9 million
· Gross Margin for the period was 46 %, up from 31 % in Q4’15
· Positive EBITDA of NOK 0,2 million
· Profit after tax was NOK 0,6 million
Full Year 2016
· Revenue rose by 66 % to NOK 52,5 million
· Gross Margin for the year was 45 %
· EBITDA coming in at NOK -9,1 million
· Loss after tax was NOK -18,2 million
Hvis man sammenligner med Q4, så er ikke tallene veldig imponerende. Samme gross margin, litt lavere inntekter (15,9*2 = 31,8 vs 30,6).
For meg ser det ut som det ikke har skjedd noe som helst?
Min utheving:
OPERATIONAL REVIEW
During the first half of the year we continued our top line growth, increasing sales by approximately 19% versus the same period in 2016. While this growth rate is below our full year expectation, it is in line with our budget timing and reflects our expectation of accelerated sales growth during the second half of the year. In the second quarter we recorded the highest quarterly revenue in our history, and based on multiple commercial initiatives that are well underway, we anticipate strong performance in the months ahead. Customer brand support and media outreach in regions such as Brazil, China and Australia were especially effective. These initiatives helped drive exceptional growth in these regions and materially contributed to overall results. Strong growth in the US was driven by a combination of new customers and growth with our existing base. In Europe, we also saw a significant increase in new customers, although the resulting growth was somewhat offset by purchase timing related to one of our larger customers. The current outlook, including a return to more typical order patterns with this customer, further supports our expectation of accelerated growth in the second half of the year.
Profit margin, at 46%, was also within expectations, albeit on the lower end of our range. The difference from the prior year period, at 50%, was due primarily to higher costs associated with the ramp-up of additional synthetic capacity. Timing of demand with the availability of the new capacity was tight during the 1st half of the year; however, as this capacity now comes fully on line we are highly confident in the return of margins at or above the level we achieved in the prior period. Our priority during the first half of the year was to assure we could meet increasing demand. While the focus on fulfilling new customer demand will continue during the second half of the year, we will increasingly be able to meet it with additional, and more efficient, capacity. As the planned capacity becomes operational in the coming months we will shift some of our dedicated resources to process efficiencies and a strengthened cost position.
… men det ser forsåvidt greit ut, men det tar tid.
5 Likes
Har ikke hatt tid til å se på det enda, men ved første øyekast virker det som forventet, de la jo frem tall i mai med lignende vekst og margin? skal se gjennom senere
1 Like
Omsetningen snirkler seg oppover (sammenlign denne med kursen!), litt lavere marginer i H1, men det ble guidet både sterkere vekst i H2 og bedre marginer, så jeg er minst like positiv til caset etter å sett raskt gjennom rapporten.
1 Like
Så bra! Kult at de får det til.
Kurs 2014: mellom 14-15
Kurs 2017: mellom 9-10
Dette gir ikke mye mening… Har du gjort noe estimat for hva kursen bør ligge på mtp p/e og fremtidig vekst?
Jeg har satt fair price 55 kroner i 2020 med base case, men da er ikke farma priset inn i det hele tatt så oppsiden er større om de treffer med begge segmentene. Ledelsen har selv satt opp mål som er betydelig høyere enn mitt base case.
3 Likes
Ble litt Natto på meg i dag. Regner man vekk Pharmadelen så tjener selskapet nå penger. Med gode marginer og bra vekst framover kan dette bli solid butikk
“Expect to see higher growth in H2’17 as new capacity is being finalized for supply of PURE”
3 Likes
Ble litt mer på meg også
Hørte gjennom webcasten nå og de opprettholder guiding på ca 50% vekst for hele 2017 målt mot 2016. Da må jo H2 bli svært bra, får vi dessuten høyere marginer som guidet kan det bli moro
3 Likes
Jeg har oppdatert mitt estimat for bruttofortjeneste H2 i forhold til guiding om ca 50% vekst i år, men jeg blir ikke skuffet hvis det kommer inn litt lavere enn dette heller. Jeg liker utviklingen!
2 Likes
2106 er en stund til da
2 Likes
Når er rapporten?